#Arbutus Biopharma (ABUS) - Prohost Biotech

Arbutus Biopharma Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial That Includes a PD-1 Monoclonal Antibody Nivolumab

Arbutus Biopharma Announcement Today, June 21, 2023, Arbutus Biopharma ( ABUS ) announced that the first patient has been dosed in the additional treatment arm of the AB-729 Phase 2a triple combinatio...

P

Prohost Biotech

Jun 21, 2023

Could Arbutus Biopharma's Patent Harm Moderna?

Arbutus Biopharma and Moderna's Patent Challenge Arbutus Biopharma ( ABUS ) is a publicly-traded biopharmaceutical company dedicated to discovering and developing a cure for patients suffering from ch...

P

Prohost Biotech

Jul 24, 2020

Small firms developing improved CAR T immunotherapy products.

We have a few small clinical stage firms in the Prohost Portfolio that were established with the goal of designing safer and more effective versions of the very promising CAR T immuno-oncology produc...

P

Prohost Biotech

Dec 28, 2018

Victims of fear and misunderstanding

ProhostLetter #423 TOMORROW’S THERAPEUTICS TODAY For a more or less fair evaluation of biotechnology and pharmaceutical firms, analysts currently rely for their assessment on criteria that include qua...

P

Prohost Biotech

Aug 1, 2018

1m

3

News & Comments

The FDA Approves AstraZeneca Checkpoint Inhibitor Imfinzi® for a Lung Cancer. A Probable Partnership Agreement Between Arbutus and Roivant

The Food and Drug Administration (FDA) approved AstraZeneca (AZN) Checkpoint inhibitor drug Imfinzi® (durvalumab) for patients with unresectable Stage III non-small cell lung cancer (NSCLC) whose dise...

P

Prohost Biotech

Feb 22, 2018

Prohost Letter #389

Prohost Letter #389 Happy New Year 2016 Wishing You Good Health Peace of Mind Love And happiness We expect 2016 to be the year that fulfills many of our great expectations about successfully managing...

P

Prohost Biotech

Jan 2, 2016

Great News and Disappointing Setbacks. Why is Understanding Gene Editing Imperative?

Why is it Imperative to Learn About Gene Editing? Why Our Article was Delayed? We know well that many are waiting for the Part 2 of the GENE EDITING. The task looked easy but when reaching deeper into...

P

Prohost Biotech

Dec 28, 2015

Prohost Letter #388

Prohost Letter #388 TOPICS - 1. AN INDISPENSABLE SHORT INTRODUCTION 2. GENE EDITING 3. GENE THERAPY 4. CANCER IMMUNOTHERAPY 1. GENE EDITING Exon Skipping: Biomarin (BMRN); Sarepta (SRPT); These firms...

P

Prohost Biotech

Dec 2, 2015

1m

11